Products Sanofi

1 products

1.1 prescription medications

1.1.1 autoimmune
1.1.2 cardiovascular
1.1.3 infectious disease
1.1.4 metabolic
1.1.5 neurology
1.1.6 oncology
1.1.7 pain
1.1.8 diabetes
1.1.9 on counter


1.2 pipeline
1.3 management
1.4 stockholders

products
prescription medications
autoimmune

epinephrine autoinjector (auvi-q in , allerject in canada), licensed intelliject , approved fda in 2012 emergency treatment of life-threatening allergic reactions.
teriflunomide (aubagio), small molecule multiple sclerosis. approved fda in september 2012.

product recall , effects: epinephrine auto-injection devices made sanofi sa on market in u.s. , canada voluntarily recalled on october 28, 2015. reason stated sanofi products have been found potentially have inaccurate dosage delivery, may include failure deliver drug.

sanofi added following warning: if patient experiencing serious allergic reaction (i.e., anaphylaxis) did not receive intended dose, there significant health consequences, including death because anaphylaxis potentially life‑threatening condition.

in news release on october 28, 2015, sanofi canada stated actively working suppliers of alternative epinephrine auto-injectors have full stock available in canada possible. canadian customers asked return allerject product local pharmacy obtain alternate epinephrine auto-injector.

the u.s. food , drug administration filed news release confirming recall involves auvi-q on market in u.s. fda release went on provide information consumers re: exchanging device brand of product, provided on auivi-q web site. sanofi provide reimbursement out of pocket costs incurred purchase of new, alternate epinephrine auto-injectors proof of purchase.

the alternate products expected commonly replace recalled sanofi devices epipens made mylan in , pfizer—under license mylan—in canada. mylan had 85% market share of auto-injectors in in first half of 2015. maylan expected benefit recall competitor sanofi, according report published in fierce pharma newsletter of november 2, 2015: .... hard see auvi-q returning market, need redesigned , face uphill battle recapture patient trust after recall, bernstein analyst ronny gal wrote in note clients on monday. gal believes company have 95% of epinephrine auto-injector market, according fierce pharma report on november 3, 2015.

cardiovascular

clopidogrel (plavix, iscover) atherothrombosis
enoxaparin (lovenox, clexane) thrombosis (its biggest seller in 2008)
mipomersen (kynamro), antisense drug invented isis pharmaceuticals , acquired genzyme in 2008 (pre-sanofi) , approved fda in 2013 orphan disease homozygous familial hypercholesterolemia.
irbesartan (aprovel, avapro, karvea) , ramipril (delix, triatec, tritace) hypertension
alirocumab (praluent) heterozygous familial hypercholesterolemia , clinical atherosclerotic cardiovascular disease
dupilumab (dupixent) heart disease

infectious disease

antibiotics:

cefotaxime (claforan)
rifapentine (priftin)
levofloxacin (tavanic)
amoxicillin/clavulanic acid (amoklavin)


vaccines:

bacterial diseases:

cholera
diphtheria
haemophilus influenzae type b
meningococcal infections (menactra)
pertussis
pneumococcal infections
tetanus
tuberculosis
typhoid fever


viral diseases:

hepatitis a
hepatitis b
influenza
japanese encephalitis (ixiaro)
measles
mumps
poliomyelitis
rabies
rubella
varicella
yellow fever
smallpox - eradicated in 1980 (vaccine produced measure in response threat of bioterrorism)





metabolic

glimepiride (amaryl) type 2 diabetes mellitus
human insulin (insuman) type 1 , type 2 diabetes mellitus
insulin glulisine (apidra) , insulin glargine (lantus) diabetes
risedronic acid (actonel) osteoporosis , paget’s disease
sevelamer hydrochloride (renagel , renvela) end stage renal disease
carmustine implants (gliadel) cancer

neurology

sodium hyaluronate (hyalgan) blood tests
valproic acid (depakine) , valproate semisodium (depakote) epilepsy
zolpidem (ambien, ambien cr, myslee, stilnoct, stilnox, zolfresh, zolt) insomnia

oncology

alfuzosin (xatral/uroxatral) benign prostatic hyperplasia
cabazitaxel (jevtana) prostate cancer
plerixafor (mozobil) macrocycle approved fda peripheral blood stem cell mobilizer non-hodgkins lymphoma , multiple myeloma in december 2008.
aflibercept (zaltrap) recombinant fusion protein, approved in metastatic colorectal cancer in combination other agents in 2012.
clomifene (clomid) female infertility
docetaxel (taxotere) breast, lung , prostate cancer
oxaliplatin (eloxatin) colorectal cancer
sarilumab (kevzara) blood tests, lung , prostate cancer
vandetanib (caprelsa) breast, colorectal cancer , female infertility

pain

codeine (solpadol) chronic pain
ketoprofen (bi-profined) pain

diabetes

toujeo (insulin glargine) type 1 , type 2 diabetes mellitus
lantus (insulin glargine) type 1 , type 2 diabetes mellitus

over counter

fexofenadine (allegra, telfast) , triamcinolone (nasacort) allergic rhinitis
paracetamol (novaldol)
calcium carbonate (maalox, antacid)

the company produces broad range of over-the-counter products, among them allegra, icyhot muscle pain, gold bond skin irritation, , selsun blue dandruff shampoo (these brands acquired in 2010 when sanofi-aventis purchased chattem).

pipeline

as of summer of 2013, sanofi in race amgen , pfizer win approval drug inhibits pcsk9, protein slows clearance of low-density lipoprotein (ldl) cholesterol - form of cholesterol leads heart attacks. sanofi s drug discovered regeneron , called alirocumab. fda warning in march 2014 possible cognitive adverse effects of pcsk9 inhibition threw competition disarray, fda asked companies include neurocognitive testing phase iii clinical trials.

in fall 2013 sanofi announced candidate collaboration regeneron, monoclonal antibody against interleukin 6 receptor, sarilumab, had better efficacy placebo in first phase iii trial rheumatoid arthritis.

management

olivier brandicourt, chairman, chief executive officer
jean-françois dehecq general manager of sanofi creation in 1973 until 2007.

stockholders

as of 31 december 2013:

breakdown of share ownership: 8.93% l oréal, 0.27% treasury shares , 1.31% employees. remaining 89.49% publicly traded.




^ http://www.kaleopharma.com/intelliject-inc-receives-fda-approval-for-auvi-qtm-epinephrine-injection-usp/
^ katie thomas new york times. 1 february 2013 brothers develop new device halt allergy attacks
^ fda approves new multiple sclerosis treatment aubagio (press release). fda. retrieved 2012-09-14. 
^ allerject epinephrine auto-injectors recalled . 
^ http://www.allerject.ca/common/docs/en/sanofi-canada-issues-voluntary-recall-of-allerject.pdf
^ auvi-q® (epinephrine injection, usp) . 
^ commissioner, office of regulatory affairs, office of the. recalls, market withdrawals, & safety alerts - updated: sanofi issues voluntary nationwide recall of auvi-q® due potential inaccurate dosage delivery . www.fda.gov. retrieved 23 may 2017. 
^ sanofi canada issues voluntary nationwide recall of allerject® due potential inaccurate dosage . 
^ welcome epipen® 101 . 
^ reprints, cynthia koons cynthialkoons robert langreth robertlangreth. how marketing turned epipen billion-dollar business . 
^ sanofi s auvi-q recall puts mylan s rival epipen in full control of blockbuster market - fiercepharma . 
^ s open season mylan s epipen sanofi, teva stumble - fiercepharma . 
^ annual review 2008 (pdf). sanofi-aventis. retrieved 2009-04-19. 
^ lisa m. jarvis chemical , engineering news. 14 january 2008 isis, genzyme in heart drug deal
^ andrew pollack new york times. 29 january 2013 f.d.a. approves genetic drug treat rare disease
^ mozobil approved non-hodgkin s lymphoma , multiple myeloma (press release). monthly prescribing reference. 18 december 2008. retrieved 3 january 2009. 
^ cite error: named reference zaltrapfda invoked never defined (see page).
^ gina kolata new york times. 9 july 2013 rare mutation ignites race cholesterol drug
^ alirocumab on regeneron s website archived 16 april 2012 @ wayback machine.
^ john carroll fiercebiotech 7 march 2014 updated: regeneron, sanofi , amgen shares suffer on fda s frets pcsk9 class
^ john carroll fiercebiotech 22 november 2013 regeneron, sanofi hit trio of goals in first phiii test of rheumatoid arthritis drug
^ noemie bisserbe wall street journal. 20 feb. 2015 sanofi names olivier brandicourt ceo
^ annual report 2013 (pdf). sanofi-aventis. retrieved 13 april 2014. 
^ marketwatch 29 april 2011 total cfo says firm cut sanofi stake under 5%

cite error: there <ref group=upper-alpha> tags or {{efn-ua}} templates on page, references not show without {{reflist|group=upper-alpha}} template or {{notelist-ua}} template (see page).